← Insider buys

TECH

Bio-Techne Corporation · Healthcare

Insiders sold $437K of Bio-Techne Corporation in the last 12 months and bought none

$0Bought, 12 mo
$437KSold, 12 mo
$11.4BMarket cap

TECH over the last year

No insider buys filed in this year

TECH after insider buys

3 months after each buy, from the first price a copier could get.

No buys have 3 months of prices yet. A record shows here at 3.

Congress

Members reported 31 trades in TECH since 2023.

Every filing

96 insider filings since 2016, newest first

TECHSell

Amy E. Herr · Director

$320K−70.0%May 12
TECHSell

Amy E. Herr · Director

$117K−41.0%Feb 19
TECHSell

Robert Baumgartner V · Director

$1.2M−27.0%Aug 12
TECHSell

John L Higgins · Director

$335K−10.0%May 16
TECHSell

Roeland Nusse · Director

$801K−19.0%Mar 11
TECHSell

Roeland Nusse · Director

$718K−15.0%Sep 1
TECHSell

Charles R. Kummeth · CEO

$7.1M−6.0%Jul 25
TECHSell

Charles R. Kummeth · CEO

$27KJun 9
TECHSell

Brenda S. Furlow · SVP - GC

$677K−18.0%Dec 9
TECHSell

John L Higgins · Director

$949K−31.0%Aug 12
TECHSell

John L Higgins · Director

$584K−26.0%Jun 9
TECHSell

Charles R. Kummeth · CEO

$1.9M−3.0%Jun 9
TECHBuy

Robert Baumgartner V · Director

$106K+3.0%May 11
TECHSell

Kim Kelderman · Pres Diagnostics, Genom

$253K−100.0%Nov 23
TECHSell

Norman David Eansor · Pres-Protein Sciences

$13.7M−93.0%Nov 16
TECHSell

James Hippel · CFO

$4.7M−46.0%Nov 3
TECHSell

James Hippel · CFO

$400K−7.0%Nov 1
TECHSell

Kim Kelderman · Pres Diagnostics, Genom

$435K−100.0%Sep 24
TECHSell

Randolph C Steer · Director

$4.1M−61.0%Sep 9
TECHSell

James Hippel · CFO

$5.1M−48.0%Sep 7
TECHSell

Brenda S. Furlow · SVP - GC

$3.5M−47.0%Sep 7
TECHSell

Norman David Eansor · Pres-Protein Sciences

$774K−54.0%Sep 2
TECHSell

Brenda S. Furlow · SVP - GC

$2.5M−40.0%Sep 2
TECHSell

Roeland Nusse · Director

$1.9M−37.0%Aug 25
TECHSell

Robert Baumgartner V · Director

$1.9M−29.0%Aug 25
TECHSell

Brenda S. Furlow · SVP - GC

$1.7M−32.0%Aug 23
TECHSell

James Hippel · CFO

$4.8M−48.0%Aug 10
TECHSell

James Hippel · CFO

$4.6M−52.0%Jul 14
TECHSell

Charles R. Kummeth · CEO

$5.6M−7.0%Jun 21
TECHSell

Charles R. Kummeth · CEO

$3.4M−4.0%Jun 16
TECHSell

Kim Kelderman · Pres Diagnostics, Genom

$351K−100.0%Jun 11
TECHSell

James Hippel · CFO

$4.2M−52.0%Jun 9
TECHSell

Kim Kelderman · Pres Diagnostics, Genom

$358K−51.0%May 27
TECHSell

James Hippel · CFO

$4.0M−52.0%Feb 17
TECHSell

Brenda S. Furlow · SVP - GC

$4.0M−62.0%Feb 17
TECHSell

Roeland Nusse · Director

$2.3M−47.0%Feb 10
TECHSell

Kim Kelderman · Pres Diagnostics, Genom

$320K−49.0%Feb 9
TECHSell

Norman David Eansor · Pres-Protein Sciences

$12.5M−96.0%Feb 9
TECHSell

Charles R. Kummeth · CEO

$6.9M−12.0%Jan 20
TECHSell

James Hippel · CFO

$3.3M−52.0%Jan 13
TECHSell

Charles R. Kummeth · CEO

$1.5M−3.0%Dec 9
TECHSell

Brenda S. Furlow · SVP - GC

$3.3M−64.0%Dec 2
TECHSell

Robert Baumgartner V · Director

$1.5M−34.0%Nov 20
TECHSell

Alpna Seth · Director

$1.5M−70.0%Nov 19
TECHSell

James Hippel · CFO

$3.4M−55.0%Nov 12
TECHSell

Randolph C Steer · Director

$3.0M−66.0%Nov 10
TECHSell

John L Higgins · Director

$1.5M−53.0%Nov 10
TECHSell

James Hippel · CFO

$4.5M−64.0%Nov 6
TECHSell

Brenda S. Furlow · SVP - GC

$2.5M−68.0%Jul 13
TECHSell

James Hippel · CFO

$6.5M−72.0%Jul 8
About Bio-Techne Corporation

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.